Last updated: March 13, 2026
What is NDC 00904-7107?
NDC 00904-7107 identifies Remdesivir (Veklury), an antiviral medication approved by the FDA in October 2020 for treating COVID-19 in hospitalized patients. The drug is developed by Gilead Sciences.
Market Scope and Competitive Landscape
Market Size and Usage
- Global COVID-19 treatment market reached approximately $30 billion in 2022. Expected growth is minor, due to increasing vaccination rates and treatment options.
- Remdesivir's market share peaked during 2020-2021, accounting for an estimated 50% of antiviral treatments for COVID-19 in the US.
- Expected market volume: approximately 10 million treatment courses globally in 2022, with a projected compound annual growth rate (CAGR) of 2-3% through 2025.
Key Competitors
- Pfizer's Paxlovid: Oral antiviral, gained rapid adoption.
- Merck's Lagevrio (molnupiravir): Oral antiviral, with emergency use authorization (EUA).
- Other supportive therapies: Dexamethasone, monoclonal antibodies.
Treatment Dynamics
- Remdesivir is administered intravenously over 5-10 days, typically in hospital settings.
- Usage declined in late 2022 as oral antivirals gained popularity for early outpatient treatment.
- Variability in adoption depends on regulatory approvals, hospital protocols, and insurance coverage.
Regulatory and Reimbursement Landscape
- Approved or authorized in over 60 countries.
- Reimbursed primarily through government programs like Medicare, Medicaid, and private insurers in the US.
- Price negotiations and utilization caps impact revenue potential.
Price Trends and Projections
Historical Pricing Data
- 2019-2020: The drug was in development; prices were not publicly disclosed.
- 2020: Gilead initially set the list price at $520 per vial, totaling $3,120 for a typical 6-day treatment course (6 vials).
- 2021: The price remained stable amid high demand.
Current Pricing and Market Factors
- Actual prices paid by healthcare providers tend to be lower due to negotiations.
- Average invoice price: estimated between $390 and $450 per vial.
- Insurance Reimbursement: Medicare has approved a $520 per vial rate for outpatient use in 2022, but hospitals often pay less due to negotiations.
Projected Price Trends (2023-2025)
| Year |
Expected Price per Vial |
Comments |
| 2023 |
$350 - $400 |
Price pressure from generic / biosimilar options, increased competition with oral antivirals |
| 2024 |
$330 - $380 |
Market saturation, decline in demand for hospitalized treatments |
| 2025 |
$310 - $350 |
Continued market share decline, shift toward outpatient treatments |
Market Drivers Affecting Prices
- Generic/formulation competition: Available in some regions as off-label or unlicensed versions.
- Supply chain dynamics: Manufacturing capacity has increased, stabilizing procurement costs.
- Regulatory status: EUA transitions to full approval could influence pricing and procurement policies.
- Policy shifts: US government stockpiling and stock release policies impact demand instability.
Revenue and Profitability Outlook
- Projected global sales of remdesivir are expected to decline by 15-20% annually from 2023 onwards.
- Gilead's revenue attributable to remdesivir may peak at approximately $3 billion in 2022 before gradually decreasing.
- Margins are likely to compress from 60-70% in 2022 to 40-50% by 2025 as generic competition and price pressures intensify.
Key Takeaways
- The COVID-19 antiviral market is mature, with remdesivir's peak demand likely behind.
- Pricing is volatile, influenced by negotiations, competition, and regulatory transitions.
- Expected decline in sales volume and prices from 2023 onward signals reduced profitability.
- Gilead may need to diversify their antiviral portfolio to sustain growth.
FAQs
1. Will remdesivir's price decline further post-2023?
Yes. Market saturation, increased competition from oral antivirals, and regulatory shifts are expected to lower procurement prices progressively.
2. How does remdesivir compare with new oral COVID-19 treatments?
Oral treatments like Paxlovid and Lagevrio are more convenient, leading to decreased hospital use and diminished remdesivir demand.
3. Are biosimilars or generics expected to impact remdesivir’s pricing globally?
In some countries, biosimilars are entering the market, which will pressure prices downward, especially outside the US.
4. What are the main factors that could sustain remdesivir prices?
Regulatory barriers delaying biosimilar entry, supply chain constraints, or renewed indications could temporarily stabilize prices.
5. Are there new indications for remdesivir beyond COVID-19?
Currently, remdesivir’s primary indication remains COVID-19; ongoing research into other viral illnesses has not yet resulted in approval.
Sources
[1] Gilead Sciences. (2022). Veklury (Remdesivir) Prescribing Information.
[2] IQVIA. (2022). Global COVID-19 antiviral treatment market report.
[3] U.S. Food and Drug Administration. (2020). Remdesivir Emergency Use Authorization.
Note: All projections are estimates based on current market dynamics and are subject to change as new data emerge.
